ZeCardio Therapeutics

www.zecardiotherapeutics.com ↗ ·Barcelona ·Seed

ZeCardio Therapeutics is a Barcelona-based biopharmaceutical company that discovers new drugs for cardiovascular diseases that have no current treatment. It was spun out in 2019 from ZeClinics, a zebrafish contract research organisation (CRO), and is built on ZeCardio, its patent-pending platform for screening and analysing zebrafish models. It has three programmes: cardioprotection against the cardiotoxic effects of cancer therapies, which is the most advanced; cardiomyopathies; and regeneration of heart tissue after acute cardiac damage. The company raised €812,000 from more than 400 investors in a 2020 equity crowdfunding round on Capital Cell, and in 2025 it announced a further round of about $1.5M to expand its in-house research and preclinical studies.

Founded

2019

Founders

Total funds raised

€800K

SectorsBiotech, Drug Discovery, Cardiovascular, Pharmaceuticals Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Davide D'Amico

Co-founder & CEO

Javier Terriente

Co-founder & CSO

Global models 4

Cardurion Pharmaceuticals

United States · www.cardurion.com ↗

A venture-backed biotech that discovers and develops new small-molecule drugs for heart failure and cardiomyopathies, which are also ZeCardio's disease targets.

~$500MComparable

Tenaya Therapeutics

United States · www.tenayatherapeutics.com ↗

Uses its own discovery platform to develop therapies for cardiomyopathies and heart regeneration, the same programme mix as ZeCardio.

~$240M (pre-IPO)Comparable

Lexeo Therapeutics

United States · www.lexeotx.com ↗

A VC-funded biotech that develops treatments for genetic cardiomyopathies with no approved therapy, aiming to license or develop its pipeline programmes.

~$185M (pre-IPO)Comparable